ClinicalTrials.gg
CompletedNCT01670721AFEQTUpdated Nov 28, 2016Results posted

Colorectal Cancer Metastatic

A Phase 3 interventional study of AFLIBERCEPT and Irinotecan in Colorectal Cancer Metastatic, sponsored by Sanofi. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-11-28.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
175
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies testing aflibercept in Colorectal Neoplasms — 1 open to participants now, 2 under way, none of them phase 3. aflibercept · Colorectal Neoplasms.

Enrollment
5th of 24
175 · median 63
Started
2012
with 6 others
Phase 3
4 of 24
none open now
Registered
5th of 24
by date
Lead sponsor
8 of 24
Sanofi

Among the 24 studies testing aflibercept in Colorectal Neoplasms, this one is the 5th largest by enrollment, is one of 7 that started in 2012, is one of 4 in phase 3, and was the 5th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

1 of the 24 studies testing aflibercept in Colorectal Neoplasms is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About aflibercept

aflibercept: first FDA approval 2011 (EYLEA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing aflibercept in Colorectal Neoplasms, or all of them as a file.
02

Study summary

Primary Objective:

To evaluate the safety of aflibercept in participants with mCRC treated with irinotecan/5-Fluorouracil (5-FU) combination (FOLFIRI) after failure of an oxaliplatin-based regimen (participants similar to those evaluated in the VELOUR trial [EFC10262, NCT00561470]) according to side effects prevention and management guidelines.

Secondary Objective:

To document the Health-Related Quality of Life (HRQL) of aflibercept in this participant population.

Read the detailed description

Each participant was treated until disease progression (DP), unacceptable toxicity, death, Investigator's decision or participant's refusal for further treatment (whichever come first). Participants were followed-up during treatment and for at least 30 days after its last study treatment (either Aflibercept or FOLFIRI) administration, up to a maximum of 6 months.

03

Conditions studied

  • Colorectal Cancer Metastatic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically proven adenocarcinoma of the colon or rectum.
  • disease.
  • Age ≥18 years.
  • (ECOG) performance status (PS) 0-1.
  • One and only one prior chemotherapeutic regimen for metastatic disease. This prior chemotherapy must be an oxaliplatin containing regimen. Participants must progressed during or following the last administration of the oxaliplatin based chemotherapy. Participants relapsing within 6 months of completion of oxaliplatin chemotherapy were also eligible.
  • Participants must be affiliated to a Social Security System.

Exclusion criteria

Exclusion criteria:

Related to Methodology

  • Prior therapy with irinotecan; (ANC) \<1.5 x 109/L; count \<100 x 109/L; \<9.0 g/dL; Total >1.5 x (ULN); Transaminases >3 x ULN (unless liver are present, 5 x ULN in that case); Alkaline phosphatase >3 x ULN (unless liver metastasis are present, 5 x ULN in that case).
  • Less than 4 weeks elapsed from prior radiotherapy or prior chemotherapy or major surgery to the time of inclusion or until the surgical wound was fully healed whichever came later (48 hours in case of minor surgical procedure or until wound full healing observed).
  • Treatment with any drug within 30 days prior to inclusion.
  • AEs (with exception of alopecia, peripheral sensory neuropathy and those listed in specific exclusion criteria) from any prior anti cancer therapy of grade >1 National Cancer Institute [NCI CTCAE] v.4.0 at the time of inclusion.
  • History of , uncontrolled spinal cord compression, or carcinomatous meningitis or new evidence of brain or .
  • Other prior . Basal cell or squamous cell skin cancer, carcinoma in situ of the cervix or any other cancer from which the participant had been disease free for >5 years were allowed.
  • Any of the following within 6 months prior to inclusion: myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, (NYHA) class III or IV congestive heart failure, stroke or .
  • Any of the following within 3 months prior to inclusion: Grade 3-4 gastrointestinal bleeding/hemorrhage, treatment resistant peptic ulcer disease, erosive oesophagitis or gastritis, infectious or inflammatory bowel disease, diverticulitis, pulmonary embolism or other uncontrolled thromboembolic event.
  • Occurrence of deep vein thrombosis within 4 weeks, prior to inclusion.
  • Known acquired immunodeficiency syndrome (AIDS)-related illnesses or known human deficiency virus () disease requiring antiretroviral treatment.
  • Any severe acute or chronic medical condition, which could impair the ability of the participant to participate to the study or to interfere with interpretation of study results.
  • Pregnant or breast-feeding women. Positive pregnancy test for women of .
  • Participants with reproductive potential (female and male) who did not agree to use a method of during the study treatment period and for at least 6 months following completion of study treatment. The definition of effective method was left to the investigator's judgment.

Related to Aflibercept:

  • Urine protein-creatinine ratio (UPCR) >1 on morning spot urinalysis or proteinuria > 500 mg/24-h.
  • Serum creatinine >1.5 x ULN . If creatinine 1.0-1.5 x ULN, , calculated according to Cockroft-Gault formula, \<60 ml/min will exclude the participant.
  • Uncontrolled hypertension (blood pressure >140/90 mmHg or systolic blood pressure >160 mmHg when diastolic blood pressure \<90 mmHg, on at least 2 repeated determinations on separate days, or upon clinical judgement within 3 months prior to study inclusion.
  • Participants on anticoagulant therapy with unstable dose of warfarin and/or having an out-of-therapeutic range (INR) (>3) within the 4 weeks prior to inclusion.
  • Evidence of bleeding diathesis or underlying coagulopathy (e.g. INR >1.5 without vitamine K antagonist therapy), non-healing wound.

Related to FOLFIRI

  • Known dihydropyrimidine dehydrogenase deficiency.
  • Predisposing colonic or small bowel disorders in which the symptoms were uncontrolled as indicated by baseline of >3 loose stools daily.
  • Prior history of chronic enteropathy, inflammatory enteropathy, chronic diarrhea, unresolved bowel obstruction/sub-obstruction, more than hemicolectomy, extensive small intestine resection with chronic diarrhea.
  • History of anaphylaxis or known intolerance to atropine sulphate or loperamide or appropriate antiemetics to be administered in conjunction with FOLFIRI.
  • Treatment with concomitant anticonvulsivant agents that are cytochrome P450 3A4 () inducers (phenytoin, phenobarbital, carbamazepine), unless discontinued >7 days.
  • Participants with known Gilbert's syndrome.

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
175 participants (actual)

Study arms

  • Experimental
    Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)

    Aflibercept 4 mg/kg intravenous (IV) infusion over 60 minutes followed by Irinotecan 180 mg/m\^2 IV infusion over 90 minutes and Leucovorin 400 mg/m\^2 IV infusion over 120 minutes at the same time followed by 5-FU 400 mg/m\^2 IV bolus over 2-4 minutes followed by 5-FU 2400 mg/m\^2 continuous IV infusion over 46 hours on Day 1 of each cycle (1 Cycle = 2 weeks), until DP, unacceptable toxicity, death, Investigator's decision or participant's refusal of further treatment.

    Drug: AFLIBERCEPT · Drug: Irinotecan · Drug: Fluorouracil · Drug: Leucovorin

Interventions

  • Pharmaceutical form:Concentrate for solution for infusion; Route of administration: Intravenous

    Also known as: AVE0005

  • Pharmaceutical form:Concentrate for solution for infusion; Route of administration: Intravenous

  • Pharmaceutical form:Concentrate for solution for infusion; Route of administration: Intravenous

  • Pharmaceutical form:Concentrate for solution for infusion; Route of administration: Intravenous

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Adverse Events (AEs)

    Any untoward medical occurrence in a participant who received investigational medicinal product (IMP) was considered an AE without regard to possibility of causal relationship with this treatment. Treatment-emergent adverse events (TEAEs) were defined as AEs that developed or worsened or became serious during on-treatment period. On-treatment period was defined as the time from the first dose of treatment to 30 days after the last dose of treatment (either Aflibercept or FOLFIRI). A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. Any TEAE included participants with both serious and non-serious AEs.

    Time frame: Baseline upto 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure:723 days)

Secondary outcomes

  1. Change From Baseline in Health Related Quality of Life (HRQL) European Organization for Research and Treatment for Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)

    EORTC-QLQ-C30 is a cancer-specific instrument with 30 questions for evaluation of new chemotherapy and provides an assessment of participant reported outcome dimensions. First 28 questions used 4-point scale (1=not at all,2=a little,3=quite a bit,4=very much) for evaluating 5 functional scales (physical,role,emotional,cognitive,social), 3 symptom scales (fatigue,nausea/vomiting,pain) \& other single items. For each item,high score represented high level of symptomatology/problem. Last 2 questions represented participant's assessment of overall health \& quality of life, coded on 7-point scale (1=very poor to 7=excellent). EORTC QLQ-C30 observed values and change from baseline for global health status (scoring of questions 29 \& 30) and 5 functional scales, 3 symptom scales and other single items (scoring of questions 1 to 28). Answers were converted into grading scale, with values between 0 and 100. A high score represented a favorable outcome with a best quality of life for participant.

    Time frame: Pre-dose at Baseline, Day 1 of every odd cycle; and at end of treatment (30 days after last study treatment) (maximum exposure: 99 weeks)

  2. Change From Baseline in HRQL European-Quality of Life-5 Dimension Instrument-3 Levels (EQ-5D-3L) Index Score

    EQ-5D was a standardized HRQL questionnaire consisting of EQ-5D descriptive system and Visual Analogue Scale (VAS). EQ-5D descriptive system comprised of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression measured on 3 levels (no problem, some problems \& severe problems) within a particular EQ-5D dimension. 5 dimensional 3-level system was converted into single index utility score. Possible values for single index utility score ranged from -0.594 (severe problems in all dimensions) to 1.0 (no problem in all dimensions) on scale where 1 represented best possible health state.

    Time frame: Pre-dose at Baseline, Day 1 of every odd cycle; and at end of treatment (30 days after last study treatment) (maximum exposure: 99 weeks)

  3. Change From Baseline in HRQL EQ-5D-3L VAS Score

    EQ-5D VAS was used to record a participant's rating for his/her current health-related quality of life state and captured on a vertical VAS (0-100), where 0 = worst imaginable health state and 100 = best imaginable health state. Baseline corresponded to last evaluable assessment before treatment administration.

    Time frame: Pre-dose at Baseline, Day 1 of every odd cycle; and at end of treatment (30 days after last study treatment) (maximum exposure: 99 weeks)

07

Results

Posted Nov 28, 2016

Participant flow

The study was conducted at 38 sites in France. A total of 182 participants were screened between 08 August 2012 and 30 June 2014, out of which 175 participants were enrolled and treated.

Participant flow — Overall Study
MilestoneAflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)
Started175
Completed122
Not completed53
Withdrew: Participant's decision15
Withdrew: Other than specified above38

Outcome measures

PrimaryPercentage of Participants With Adverse Events (AEs)

Any untoward medical occurrence in a participant who received investigational medicinal product (IMP) was considered an AE without regard to possibility of causal relationship with this treatment. Treatment-emergent adverse events (TEAEs) were defined as AEs that developed or worsened or became serious during on-treatment period. On-treatment period was defined as the time from the first dose of treatment to 30 days after the last dose of treatment (either Aflibercept or FOLFIRI). A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. Any TEAE included participants with both serious and non-serious AEs.

Time frame:
Baseline upto 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure:723 days)
Reported as:
Number · Percentage of participants
Percentage of Participants With Adverse Events (AEs)
Percentage of participantsAflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)
Any TEAE100.00
Any serious TEAE40.6
Any serious related TEAE21.1
Any TEAE leading to death9.1
Any TEAE (permanent treatment discontinuation)23.4
Any TEAE (premature treatment discontinuation)16.0
SecondaryChange From Baseline in Health Related Quality of Life (HRQL) European Organization for Research and Treatment for Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)

EORTC-QLQ-C30 is a cancer-specific instrument with 30 questions for evaluation of new chemotherapy and provides an assessment of participant reported outcome dimensions. First 28 questions used 4-point scale (1=not at all,2=a little,3=quite a bit,4=very much) for evaluating 5 functional scales (physical,role,emotional,cognitive,social), 3 symptom scales (fatigue,nausea/vomiting,pain) \& other single items. For each item,high score represented high level of symptomatology/problem. Last 2 questions represented participant's assessment of overall health \& quality of life, coded on 7-point scale (1=very poor to 7=excellent). EORTC QLQ-C30 observed values and change from baseline for global health status (scoring of questions 29 \& 30) and 5 functional scales, 3 symptom scales and other single items (scoring of questions 1 to 28). Answers were converted into grading scale, with values between 0 and 100. A high score represented a favorable outcome with a best quality of life for participant.

Time frame:
Pre-dose at Baseline, Day 1 of every odd cycle; and at end of treatment (30 days after last study treatment) (maximum exposure: 99 weeks)
Reported as:
Mean · units on a scale
Change From Baseline in Health Related Quality of Life (HRQL) European Organization for Research and Treatment for Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)
units on a scaleAflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)
Baseline (n=148)69.54 ± 18.97
At Cycle 3 (n=130)-7.56 ± 19.78
At Cycle 5 (n=99)-10.86 ± 19.76
At Cycle 7 (n=72)-8.22 ± 20.00
At Cycle 9 (n=51)-9.31 ± 19.34
At Cycle 11 (n=45)-14.81 ± 21.24
At Cycle 13 (n=25)-12.67 ± 24.31
At Cycle 15 (n=24)-12.50 ± 18.22
At Cycle 17 (n=14)-14.29 ± 15.82
At Cycle 19 (n=12)-15.28 ± 11.70
At Cycle 21 (n=10)-15.83 ± 19.82
At Cycle 23 (n=6)-9.72 ± 20.01
At Cycle 25 (n=4)-8.33 ± 6.80
At Cycle 27 (n=4)-12.50 ± 15.96
At Cycle 29 (n=2)-8.33 ± 11.79
At Cycle 31 (n=2)-16.67 ± 0.00
At Cycle 33 (n=1)0.00 ± NA
At Cycle 35 (n=1)0.00 ± NA
At Cycle 37 (n=2)-8.33 ± 11.79
At Cycle 39 (n=2)-8.33 ± 11.79
At Cycle 41 (n=2)-8.33 ± 11.79
At Cycle 43 (n=2)-12.50 ± 5.89
At Cycle 45 (n=2)-4.17 ± 17.68
At Cycle 47 (n=1)0.00 ± NA
At end of study treatment (n=73)-11.19 ± 24.38
SecondaryChange From Baseline in HRQL European-Quality of Life-5 Dimension Instrument-3 Levels (EQ-5D-3L) Index Score

EQ-5D was a standardized HRQL questionnaire consisting of EQ-5D descriptive system and Visual Analogue Scale (VAS). EQ-5D descriptive system comprised of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression measured on 3 levels (no problem, some problems \& severe problems) within a particular EQ-5D dimension. 5 dimensional 3-level system was converted into single index utility score. Possible values for single index utility score ranged from -0.594 (severe problems in all dimensions) to 1.0 (no problem in all dimensions) on scale where 1 represented best possible health state.

Time frame:
Pre-dose at Baseline, Day 1 of every odd cycle; and at end of treatment (30 days after last study treatment) (maximum exposure: 99 weeks)
Reported as:
Mean · units on a scale
Change From Baseline in HRQL European-Quality of Life-5 Dimension Instrument-3 Levels (EQ-5D-3L) Index Score
units on a scaleAflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)
Baseline (n=148)0.78 ± 0.21
At Cycle 3 (n=127)-0.04 ± 0.23
At Cycle 5 (n=96)-0.08 ± 0.25
At Cycle 7 (n=72)-0.05 ± 0.20
At Cycle 9 (n=49)-0.09 ± 0.23
At Cycle 11 (n=43)-0.06 ± 0.20
At Cycle 13 (n=24)-0.09 ± 0.14
At Cycle 15 (n=25)-0.10 ± 0.16
At Cycle 17 (n=14)-0.03 ± 0.10
At Cycle 19 (n=12)-0.10 ± 0.12
At Cycle 21 (n=10)-0.03 ± 0.18
At Cycle 23 (n=6)-0.08 ± 0.15
At Cycle 25 (n=3)0.04 ± 0.22
At Cycle 27 (n=3)-0.09 ± 0.20
At Cycle 29 (n=2)-0.18 ± 0.04
At Cycle 31 (n=1)0.00 ± NA
At Cycle 37 (n=1)-0.15 ± NA
At Cycle 39 (n=1)0.00 ± NA
At Cycle 41 (n=1)0.00 ± NA
At Cycle 43 (n=1)0.00 ± NA
At Cycle 45 (n=1)0.00 ± NA
At end of study treatment (n=71)-0.20 ± 0.31
SecondaryChange From Baseline in HRQL EQ-5D-3L VAS Score

EQ-5D VAS was used to record a participant's rating for his/her current health-related quality of life state and captured on a vertical VAS (0-100), where 0 = worst imaginable health state and 100 = best imaginable health state. Baseline corresponded to last evaluable assessment before treatment administration.

Time frame:
Pre-dose at Baseline, Day 1 of every odd cycle; and at end of treatment (30 days after last study treatment) (maximum exposure: 99 weeks)
Reported as:
Mean · units on a scale
Change From Baseline in HRQL EQ-5D-3L VAS Score
units on a scaleAflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)
Baseline (n=125)69.48 ± 19.10
At cycle 3 (n=94)-6.23 ± 17.82
At cycle 5 (n=76)-7.62 ± 17.23
At cycle 7 (n=57)-7.79 ± 14.14
At cycle 9 (n=38)-7.55 ± 16.12
At cycle 11 (n=36)-8.67 ± 16.09
At cycle 13 (n=22)-8.95 ± 17.56
At cycle 15 (n=22)-12.41 ± 19.57
At cycle 17 (n=13)-10.31 ± 17.44
At cycle 19 (n=10)-15.70 ± 18.19
At cycle 21 (n=8)-15.13 ± 19.87
At cycle 23 (n=5)-8.80 ± 10.71
At cycle 25 (n=2)-13.00 ± 4.24
At cycle 27 (n=3)-15.67 ± 9.81
At cycle 29 (n=2)-17.50 ± 3.54
At cycle 31 (n=1)-15.00 ± NA
At cycle 37 (n=1)-15.00 ± NA
At cycle 39 (n=1)-15.00 ± NA
At cycle 41 (n=1)-15.00 ± NA
At cycle 43 (n=1)-15.00 ± NA
At cycle 45 (n=1)-15.00 ± NA
At end of study treatment (n=55)-13.05 ± 20.82

Adverse events

Collected over All Adverse Events (AE) were collected from signature of the informed consent form up to the final visit (Day 723) regardless of seriousness or relationship to investigational product.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Aflibercept + FOLFIRI(Irinotecan, 5-Fluorouracil & Leucovorin)—71/175 (40.6%)172/175 (98.3%)
Most frequent serious events
Showing 10 of 69
Most frequent serious events
EventAflibercept + FOLFIRI(Irinotecan, 5-Fluorouracil & Leucovorin)
DISEASE PROGRESSIONGeneral disorders9/175
DIARRHOEAGastrointestinal disorders8/175
GENERAL PHYSICAL HEALTH DETERIORATIONGeneral disorders8/175
PULMONARY EMBOLISMRespiratory, thoracic and mediastinal disorders4/175
ABDOMINAL PAINGastrointestinal disorders3/175
INTESTINAL OBSTRUCTIONGastrointestinal disorders3/175
PYREXIAGeneral disorders3/175
FEBRILE NEUTROPENIABlood and lymphatic system disorders2/175
NAUSEAGastrointestinal disorders2/175
SUBILEUSGastrointestinal disorders2/175
Most frequent other events
Showing 10 of 30
Most frequent other events
EventAflibercept + FOLFIRI(Irinotecan, 5-Fluorouracil & Leucovorin)
DIARRHOEAGastrointestinal disorders121/175
ASTHENIAGeneral disorders98/175
NAUSEAGastrointestinal disorders86/175
STOMATITISGastrointestinal disorders83/175
HYPERTENSIONVascular disorders74/175
WEIGHT DECREASEDInvestigations68/175
DECREASED APPETITEMetabolism and nutrition disorders59/175
VOMITINGGastrointestinal disorders47/175
EPISTAXISRespiratory, thoracic and mediastinal disorders43/175
NEUTROPENIABlood and lymphatic system disorders39/175

Baseline characteristics

Age, Continuous
Age, Continuous(years)Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)
Mean64.5 ± 11.0
Sex: Female, Male
Sex: Female, Male(Participants)Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)
Female77
Male98
08

Study locations

1 site
  • Administrative office
    Paris, France
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2012, a primary completion of Jun 2015 and a completion of Jun 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2016, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2012
First posted
Aug 22, 2012
Start
Aug 2012
Primary completionActual
Jun 2015
CompletionActual
Jun 2015
Results first posted
Nov 28, 2016
Last update
Nov 28, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 28, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01670721
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Aug 22, 2012
Start date
Aug 2012
Primary completion
Jun 2015
Completion
Jun 2015
Results posted
Nov 28, 2016
Last update
Nov 28, 2016

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Aflibercept · Irinotecan

Start the discussion